

ASAYAPAKARSA: A DIAGNOSTIC PERSPECTIVE IN ATYPICAL AMLAPITTA

Shruti Rana^{1*}, Dr. Chitra^{2*}¹BAMS Final Year, Motherhood Ayurveda Medical College & Hospital, India.²Associate Professor, Department of Rog Nidan evam Vikriti Vigyan, Motherhood Ayurveda Medical College & Hospital, India.***Corresponding Author: Shruti Rana, Dr. Chitra**

BAMS Final Year, Motherhood Ayurveda Medical College & Hospital, India.

Associate Professor, Department of Rog Nidan evam Vikriti Vigyan, Motherhood Ayurveda Medical College & Hospital, India.

DOI: <https://doi.org/10.5281/zenodo.22251174>**How to cite this Article:** Shruti Rana^{1*}, Dr. Chitra^{2*}. (2026). Āsayāpakarṣa: A Diagnostic Perspective In Atypical Amlapitta. European Journal of Pharmaceutical and Medical Research, 13(9), 349–354.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 05/08/2026

Article Revised on 25/08/2026

Article Published on 01/09/2026

1. INTRODUCTION**1.1 Ayurvedic Diagnostic Approach**

Ayurvedic diagnosis is a comprehensive process directed towards understanding both the disease (*Roga*) and the individual in whom it manifests (*Rogī*). Rather than relying solely on presenting symptoms, it considers the involved *Doṣa*, affected *Dūṣya* and *Srotas*, the relevant *Sthāna/Āśaya*, and the sequence of disease formation (*Samprāpti*). The *Nidāna Pañcaka*—*Nidāna*, *Pūrvārūpa*, *Rūpa*, *Upaśaya*, and *Samprāpti*—provides a systematic framework for understanding disease from its causative factors to its clinical expression and pathogenesis.

Thus, diagnosis is not limited to identifying where a symptom is present, but also requires understanding which *Doṣa* is involved, where it is situated, and how it has reached or affected that site. The clinical expression of a *Doṣa* may vary according to its location, association, and movement. Hence, the observed site of manifestation may not always represent the primary site of *Doṣa* involvement. This becomes particularly important in conditions such as atypical *Amlapitta*, where the clinical presentation may not fully correspond to the expected site or pattern of the involved *Doṣa*.

1.2 Doṣa Gati

The understanding of *Doṣa* in Ayurveda extends beyond its state of vitiation to include its site and movement within the body. Although *Doṣas* have their natural sites and functional patterns, their distribution and movement may change in disease. Caraka describes *Doṣa Gati* in *Sūtrasthāna* 17 through the concepts of *Prakṛta* and *Vikṛta Gati*, along with changes in *Kṣaya*, *Sthāna* and *Vṛddhi*, directions such as *Ūrdhva*, *Adhaḥ* and *Tiryak*, and movement between *Śākhā*, *Koṣṭha* and *Marmāsthisandhi*.

While *Prakṛta Gati* represents the normal movement and distribution of *Doṣas*, *Vikṛta Gati* refers to their abnormal movement associated with disease. Consequently, pathological manifestation depends not

only upon the *Doṣa* involved but also upon its location and movement. When a *Doṣa* moves away from its usual site, it may interact with different *Dūṣya* and *Srotas*, potentially producing manifestations that differ from those expected at its normal location.

Therefore, the site at which a disease becomes clinically evident cannot always be interpreted independently of the movement of the involved *Doṣa*. Diagnostic interpretation requires attention to the relationship between the manifested site and the underlying *Doṣa*–*Sthāna*. Among the various patterns of abnormal *Doṣa* movement, *Āsayāpakarṣa* becomes particularly relevant when a *Doṣa* is displaced from its expected *Āśaya*, providing a possible explanation for manifestations that appear discordant with its usual site. This forms the conceptual basis for examining *Āsayāpakarṣa* as a diagnostic consideration in atypical disease presentations.

1. Āsayāpakarṣa: Classical Concept, Pathogenesis and Diagnostic Significance**2.1 Etymology**

The term *Āsayāpakarṣa* comprises *Āśaya* and *Apakarṣa*. *Āśaya* refers to the seat, abode, or usual site in which a *Doṣa* is situated, while *Apakarṣa* denotes drawing away or displacement from a particular position. Thus,

Āśayāpakarṣa denotes the displacement of a *Doṣa* from its physiological *Āśaya*.

2.2 Classical Basis

A classical description of the phenomenon underlying *Āśayāpakarṣa* is found in the discussion of *Doṣa* disturbance. While describing the consequences of different combinations of *Doṣa* *Vṛddhi* and *Kṣaya*, Caraka describes the displacement of normally situated *Pitta* by *Vāta* when *Kapha* is diminished:

Prakṛtiṣṭhaṃ yadā pittam mārutaḥ śleṣmaṇaḥ kṣaye |
Sthānād ādāya gātreṣu yatra yatra visarpati ||
Tadā bhedaś ca dāhaś ca tatra tatrānavasthitaḥ |
Gātradeṣe bhavaty asya śramo daurbalyam eva ca ||

The passage describes that, when *Kapha* is diminished, *Vāta* draws *Pitta*, which is in its normal state, away from its *Sthāna* and carries it to different parts of the body. At the sites to which it is carried, manifestations such as *Bheda* and *Dāha*, along with *Śrama* and *Daurbalya*, are produced. Thus, the verse directly describes a change in the location of a normally situated *Doṣa* and the consequent manifestation of symptoms at the new site.

The *Vidyotinī* commentary of Kāśīnātha Pāṇḍeya and Gorakhanātha Caturvedī explicitly identifies this pathological state as *Āśayāpakarṣa*. The commentary explains that a *Doṣa* in its normal state is drawn away from its own site by aggravated *Vāta* and carried to another location, where it produces pathological manifestations.

The classical passage provides the textual description of the phenomenon, while the commentary provides an explicit conceptual interpretation of that phenomenon as *Āśayāpakarṣa*.

2.3 Doṣa–Āśaya Relationship and Diagnostic Significance

In Ayurveda, the relationship between a *Doṣa* and its usual *Āśaya* or *Sthāna* is relevant to understanding its clinical expression. The manifestation of a *Doṣa* is influenced not only by its state but also by the site in which it is situated and its association with the local *Dūṣya* and *Srotas*.

In *Āśayāpakarṣa*, this usual relationship is altered, as the *Doṣa* is displaced from its physiological *Āśaya*. This is conceptually distinct from *Doṣa* *Vṛddhi*: while *Vṛddhi* primarily denotes an increased or aggravated state of a *Doṣa*, *Āśayāpakarṣa* primarily concerns its altered localization. These concepts may coexist, but displacement should not be understood merely as another expression of *Doṣa* increase. Consequently, a *Pitta*-like manifestation appearing at an unusual site should not automatically be interpreted as primary *Pitta* *Vṛddhi* at that site.

This distinction shifts the diagnostic enquiry from simply asking, “Which *Doṣa* explains this symptom?” to also

considering whether the *Doṣa* is actually aggravated at the site or whether its presence there may be related to an altered *Doṣa–Āśaya* relationship.

2.4 Pathogenesis and Role of Vāta

Vāta is associated with movement and propulsion within the body, and its *Chala* property reflects its mobile nature. When *Vāta* becomes aggravated, its abnormal movement may disturb the normal localization of other *Doṣas*. Thus, the role of *Vāta* in *Āśayāpakarṣa* is not merely that of an associated *Doṣa*, but that of a factor capable of altering the location of another *Doṣa*.

This relationship is directly illustrated in the classical description discussed above. Caraka describes *Prakṛtiṣṭha* *Pitta* being taken away from its *Sthāna* by *Māruta* and carried to different parts of the body. The *Vidyotinī* commentary further explains this as movement of a *Doṣa* from its own site to another location under the influence of *Vāta*. A similar displacement of *Kapha* is also described in the same context. Thus, the classical account provides the basis for understanding *Vāta* as the factor responsible for the displacement of a normally situated *Doṣa*.

Conceptually, the process may therefore be understood as a sequence of *Vāta* *Prakopa* and abnormal movement, followed by displacement of the *Doṣa* from its physiological *Āśaya* and relocation to another *Sthāna*. At the altered site, the displaced *Doṣa* may interact with the local *Dūṣya* and *Srotas*, and its clinical expression may consequently be influenced by this altered localization.

2. Amlapitta : Classical Understanding

3.1 Etymology and Definition

The term *Amlapitta* is explained through its association with *Amla* and *Pitta*. The *Nirukti* describes it as “*amlam ca pittam amlapittam*,” while the *Madhukośa* further characterizes it as *Pitta* that has undergone *Vidagdhatva* and acquired an *Amla* character. A more specific description is provided by *Mādhava Nidāna*, which describes *Amlapitta* in relation to *Pitta* undergoing *Vidagdhatva* following exposure to factors capable of provoking or disturbing *Pitta*.

The description establishes *Vidagdha* *Pitta* as a central feature in the classical understanding of *Amlapitta*. The verse also indicates the role of *Pitta*-provoking dietary and other causative factors in the development of this altered state.

Amlapitta is also referred to in other classical sources. Caraka *Samhitā* mentions *Amlapitta* in the context of *Grahāṇī Cikitsā Adhyāya*, while *Kāśyapa Samhitā* refers to the condition as *Śukta*.

3.2 Samprāpti and Classical Clinical Manifestations

The classical development of *Amlapitta* may be understood as a sequence beginning with relevant *Nidāna*, followed by disturbance of *Pitta* and *Agni*, and

culminating in the manifestation of characteristic *Rūpa*. The classical text describes *Pitta Sañcaya*, followed by *Pitta Vṛddhi* and *Prakopa*, with subsequent development of *Vidagdhatva* and predominance of *Amla-bhāva*. *Āmāśaya* is described as the principal *Adhiṣṭhāna*, with *Annavaha Srotas* involved in the disease process; *Rasa* and *Rakta Dhātu* are identified among the associated *Dūṣya*, while *Mandāgni* and *Vimārgagamana* form relevant components of the *Samprāpti*.

The characteristic clinical manifestations described by *Mādhava Nidāna* include *Avipāka*, *Klama*, *Utkleśa*, *Tiktāmla Udgāra*, *Gaurava*, *Hṛt-kaṇṭha-dāha*, and *Aruci*, representing the characteristic clinical expression described in the classical text. The subsequent verses further describe manifestations associated with the clinical subdivisions of *Amlapitta*.

3.3 Global and Indian Prevalence of GERD

Gastroesophageal reflux disease (GERD/GORD) is one of the most common gastrointestinal disorders worldwide. A systematic review and meta-analysis including **102 studies from 37 countries and 469,899 participants** reported a pooled global prevalence of **13.98%**. Based on the 2017 UN world population estimate of **7,383,008,820**, the estimated number of individuals affected was **1,032,144,633**, approximately **1.03 billion people**.

Calculation

$$7,383,008,820 \times 13.98 / 100 = 1,032,144,633$$

Thus, approximately **1.03 billion individuals worldwide** were estimated to have GORD in this analysis.

More recent Global Burden of Disease 2021 data estimated **825.60 million prevalent GERD cases globally in 2021**, with the global burden increasing substantially since 1990.

Table 1: Global Epidemiological Estimates of GERD/GORD.

Parameter	Data
Studies included in global meta-analysis	102
Countries represented	37
Participants	469,899
Global pooled GORD prevalence	13.98%
Population used for global estimate	7,383,008,820
Estimated global GORD population	1,032,144,633 (~1.03 billion)
GBD 2021 estimated prevalent GERD cases	825.60 million

For India, a meta-analysis of **9 population-based studies involving 20,614 participants** reported a pooled GERD prevalence of **15.57% (95% CI: 11.05–20.71%)**. Reported prevalence among individual Indian studies ranged from **5% to 28.5%**.

Table 2: GERD Prevalence in the Indian Population.

Parameter	Data
Studies included	9
Total participants	20,614
Pooled Indian GERD prevalence	15.57%
Range among individual studies	5–28.5%

3.4 Evidence for Dietary Involvement in GERD

Dietary and eating-related factors have been repeatedly associated with GERD. A systematic review including **72 studies** identified several dietary and lifestyle factors associated with GERD, including very hot food, high-fat dietary intake, rapid eating, and eating beyond fullness.

Another systematic review examining dietary intake and reflux disease identified associations with **high-fat, spicy, fried, salty, citrus and carbonated foods**.

Evidence from intervention studies also supports a relationship between dietary modification and GERD-related outcomes. A systematic review and meta-analysis of dietary interventions included **21 intervention studies**, including randomized controlled trials

examining high-fat diets, carbohydrate composition, eating speed and other dietary interventions.

These findings demonstrate that dietary factors are important in the occurrence and aggravation of reflux-related symptoms and provide a contemporary parallel to the Ayurvedic concept of *Pitta-Prakopaka Ahāra*.

3.5 Ayurvedic Evidence for *Pitta-Prakopaka Ahāra-Vihāra*

In Ayurveda, *Amlapitta* is described in association with disturbance of *Pitta* and *Agni*, with *Pitta-Prakopaka Ahāra-Vihāra* functioning as important *Nidāna*. Clinical studies demonstrate frequent exposure to such factors among patients with *Amlapitta*.

A study by Baragi and Vyas involving **138 patients with *Urdhwaga Amlapitta*** reported the following dietary factors:

Table 3: Dietary *Nidāna* reported in *Urdhwaga Amlapitta*.

<i>Ahāra Nidāna</i>	Patients	Percentage
<i>Katu Ahāra</i>	137/138	99.3%
<i>Amla Ahāra</i>	132/138	95.65%
<i>Guru Ahāra</i>	125/138	90.57%
<i>Snigdha Ahāra</i>	119/138	86.23%
<i>Viruddha Ahāra</i>	113/138	81.88%
<i>Abhiṣyandi Ahāra</i>	113/138	81.88%

Ati-Uṣṇa Ahāra	102/138	73.90%
Vidāhi Ahāra	71/138	51.44%
Piṣṭāṇna	65/138	47.10%
Non-vegetarian diet	62/138	44.92%

Another clinical study reported *Pitta-Prakopaka Ahāra* in 80% of patients with *Amlapitta*. Other reported factors included *Ati-Uṣṇa Ahāra* (72.5%), *Ati-Guru Ahāra* (65%), *Ajīrṇa-producing Ahāra* (57.5%), *Ati-Amla Ahāra* (55%) and *Vidāhi Bhojana* (52.5%). *Vegavidharana* was reported in 90% and *Divāsvāpa* in 62.5% of patients.

Table 4: Reported *Pitta-Prakopaka Nidāna* in an *Amlapitta* clinical study.

<i>Nidāna</i>	Percentage
<i>Pitta-Prakopaka Ahāra</i>	80%
<i>Ati-Uṣṇa Ahāra</i>	72.5%
<i>Ati-Guru Ahāra</i>	65%
<i>Ajīrṇa-producing Ahāra</i>	57.5%
<i>Ati-Amla Ahāra</i>	55%
<i>Vidāhi Bhojana</i>	52.5%
<i>Vegavidharana</i>	90%
<i>Divāsvāpa</i>	62.5%

Thus, Ayurvedic clinical evidence demonstrates that recognizable *Pitta-Prakopaka Ahāra-Vihāra* are frequently present among patients diagnosed with *Amlapitta*, supporting the classical understanding of *Nidāna* involvement.

3.6 Interpretation of *Pitta-Prakopaka Ahāra* and the Possibility of Altered Doṣa Localization

Dietary factors are frequently reported in GERD and *Amlapitta*, particularly *Pitta-Prakopaka Ahāra* such as

Katu, Amla, Guru, Snigdha, Uṣṇa and *Vidāhi Ahāra*. Clinical evidence also indicates that *Pitta-Prakopaka Ahāra* is an important dietary factor associated with *Amlapitta*. In a clinical study involving 40 patients with *Amlapitta*, *Pitta-Prakopaka Ahāra* was reported in 80% of patients, while 20% did not report *Pitta-Prakopaka Ahāra* as the identified dietary factor. In these selected atypical presentations, the classical concept of *Āsayāpakarṣa* may be considered as one possible explanation for altered expression of *Pitta*.

From the perspective proposed in this review, the 20% of patients represent a subset in which the expected *Pitta-Prakopaka* dietary association was not reported, thereby providing a clinical context in which alternative *Samprāpti* mechanisms may be considered. One such possibility is *Vāta-mediated* alteration of *Doṣa Gati*, resulting in displacement of *Pitta* from its physiological *Āśaya*. In such cases, a *Pitta*-related manifestation at an unexpected site may not necessarily represent primary *Pitta Vṛddhi* at that site, but may potentially reflect altered localization of *Pitta*.

Proposed conceptual sequence in selected atypical presentations:

Vāta Prakopa → *Vikṛta Doṣa Gati* → *Āsayāpakarṣa* → displacement of *Pitta* from its physiological *Āśaya* → altered localization of *Pitta* → atypical clinical manifestation.

Thus, *Āsayāpakarṣa* is a possible diagnostic explanation for selected atypical presentations of *Amlapitta*, particularly where the manifested clinical features do not adequately correspond to the expected *Pitta-Āśaya-Rūpa* relationship.

Table 5: Distribution of Patients According to Reported *Pitta-Prakopaka Ahāra*.

Reported dietary association	Patients (n=40)	Percentage
<i>Pitta-Prakopaka Ahāra</i> reported	32	80%
<i>Pitta-Prakopaka Ahāra</i> not reported	8	20%
Total	40	100%

4. *Āsayāpakarṣa* as a Diagnostic Perspective in Atypical *Amlapitta*

4.1 Reconsidering the Site of Manifestation

The classical presentation of *Amlapitta* provides a recognizable *Doṣa-Sthāna-Rūpa* pattern. When a manifestation appears discordant with this pattern, however, its interpretation should not rest on the symptom alone. In particular, a *Pitta*-like manifestation does not necessarily indicate *Pitta Vṛddhi* at the site where it is observed.

This distinction is particularly significant in the *Āsayāpakarṣa* described by Caraka. The *Vidyotinī* commentary of Paṇḍit Kāśinātha Sāstrī Pāṇḍeya and Dr. Gorakhanātha Caturvedī explains that *Prakṛtiṣṭha Pitta* is displaced from its own *Sthāna* by aggravated *Vāta* and produces *Dāha* at another site. Thus, the presence of a

Pitta-like manifestation at a particular site does not by itself establish *Pitta Vṛddhi* there.

The commentary further cautions that failure to recognize this displacement may lead to *Pitta*-directed measures, whereas the appropriate approach is to pacify the aggravated *Vāta* and restore *Pitta* to its own *Sthāna*.

4.2 Relevance to Atypical *Amlapitta*

This principle becomes relevant when the clinical manifestation of *Amlapitta* does not adequately correspond with its expected *Doṣa-Sthāna* relationship. The question is then not simply whether the manifestation resembles *Pitta*, but whether *Pitta* is actually increased at that site or has reached the site through an altered process of localization.

The relevant verses in *Caraka Saṃhitā of Agniveśa* reinforce the importance of understanding the *Vikāra*, *Adhiṣṭhāna*, and *Samutthāna* before deciding on management.

Applied cautiously to this review, the classical principle raises the possibility that selected atypical manifestations of *Amlapitta* may require consideration of altered *Pitta* localization rather than assuming *Pitta Vṛddhi* alone.

4.3 Illustrative Clinical Application

Consider a patient with recurrent acidity-like manifestations who continues to experience symptoms despite appropriate *Pitta*-oriented management. Instead of simply intensifying the same approach, the clinician may reassess the *Samprāpti*, *Doṣa Gati*, and *Doṣa-Āśaya* relationship.

If the overall assessment suggests that the manifestation may not be adequately explained by *Pitta Vṛddhi*, the classical principle of *Āśayāpakarṣa* may be considered as one possible explanation.

5. Diagnostic Implications and Scope

5.1 Avoiding Site-Based Diagnostic Interpretation

In selected atypical presentations, diagnostic interpretation based primarily on the site of manifestation may lead to an incomplete understanding of the underlying *Doṣa* involvement.

Diagnostic error or misdiagnosis may potentially arise when clinicians address symptoms at the displaced site without considering the possibility of altered *Doṣa* localization.

5.2 Role of *Vāta* in Altered Localization

A symptom-based interpretation may be incomplete when the potential role of *Vāta* in altered *Doṣa* localization is not considered. Thus, when an apparently *Pitta*-dominant manifestation is observed at an unusual site, assessment should not be limited to the state of *Pitta* at that site, but should also consider whether *Vāta*-mediated displacement may have contributed to its presence there. Recognition of the role of *Vāta* therefore adds another dimension to diagnostic assessment.

5.3 Scope

The concept of *Āśayāpakarṣa* therefore may be considered as a diagnostic framework for reassessing selected atypical presentations: the site of manifestation should not be assumed to be the site of origin of the *Doṣa* disturbance. Assessment of *Doṣa*, *Āśaya*, *Gati*, and *Samprāpti*, together with *Upāśaya* and treatment response, may help in such reassessment.

6. CONCLUSION

Āśayāpakarṣa highlights that the clinical expression of a *Doṣa* may be influenced not only by its state but also by its localization. The classical description of *Vāta*-mediated displacement provides a basis for

understanding why a manifestation at an unusual site may not always indicate primary *Doṣa Vṛddhi* at that site.

In the context of atypical *Amlapitta*, consideration of *Āśayāpakarṣa* may therefore help in interpreting discordant clinical presentations by directing attention from the manifested symptom towards the underlying *Doṣa-Āśaya* relationship and *Samprāpti*. Thus, *Āśayāpakarṣa* may be regarded as a useful diagnostic perspective for selected atypical presentations.

7. REFERENCES

1. Pāṇḍeya KS, Caturvedī G, commentators. *Caraka Saṃhitā of Agniveśa, revised by Caraka and Dr̥ḍhabala, with Vidyotinī Hindi Commentary*. Varanasi: Chaukhambha Bharati Academy. *Sūtrasthāna* 1/59, 17/45–46, 18/45–47; *Nidānasthāna* 1/6.
2. Mādhavakara. *Mādhava Nidāna with Madhukośa Commentary*. Varanasi: Chaukhambha Sanskrit Sansthan. *Amlapitta Nidāna* 51/1–2.
3. Sharma AK, Sharma AK, Tewari P, Mundada S. *Āyurvedīya Roga Vijñāna evam Vikṛti Vijñāna*. Vol. II: *Roga Vijñāna*. Varanasi: Chaukhambha Visvabharati.
4. Dhureya S, Gurjar M. *Roga Nidāna evam Vikṛti Vijñāna*. Prathama Bhāga. Jaipur, Rajasthan: Ram Ayurveda Sanskrit Book Prakashan Company.
5. Baragi UC, Vyas MK. Evaluation of diet and life style in the etiopathogenesis of Urdhwaga *Amlapitta* (non-ulcer dyspepsia). *AYU.*, 2013; 34(4): 352–355. doi:10.4103/0974-8520.127705.
6. Prajapati SM, Patel BR. A comparative clinical study of *Jethimala (Taverniera nummularia Baker.)* and *Yashtimadhu (Glycyrrhiza glabra Linn.)* in the management of *Amlapitta*. *AYU.*, 2015; 36(2): 157–162. doi:10.4103/0974-8520.175551.
7. Nirwan JS, Hasan SS, Babar Z-U-D, Conway BR, Ghorī MU. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. *Scientific Reports*, 2020; 10: 5814. doi:10.1038/s41598-020-62795-1.
8. Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. *Indian J Gastroenterol*, 2021; 40(2): 209–219. doi:10.1007/s12664-020-01104-0.
9. Zhang M, Hou Z-K, Huang Z-B, Chen X-L, Liu F-B. Dietary and Lifestyle Factors Related to Gastroesophageal Reflux Disease: A Systematic Review. *Ther Clin Risk Manag*, 2021; 17: 305–323. doi:10.2147/TCRM.S296680.
10. Heidarzadeh-Esfahani N, Soleimani D, Hajiahmadi S, Moradi S, Heidarzadeh N, Nachvak SM. Dietary Intake in Relation to the Risk of Reflux Disease: A Systematic Review. *Prev Nutr Food Sci.*, 2021; 26(4): 367–379. doi:10.3746/pnf.2021.26.4.367.

11. Lakananurak N, Pitisuttithum P, Susantitaphong P, Patcharatrakul T, Gonlachanvit S. The Efficacy of Dietary Interventions in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Intervention Studies. *Nutrients*, 2024; 16(3): 464. doi:10.3390/nu16030464.
12. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. *Gut*, 2018; 67(3): 430–440. doi:10.1136/gutjnl-2016-313589.
13. GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*, 2020; 5(6): 561–581. doi:10.1016/S2468-1253(19)30408-X.
14. Zhang D, Liu S, Li Z, Wang R. Global, regional and national burden of gastroesophageal reflux disease, 1990–2019: update from the GBD 2019 study. *Ann Med*, 2022; 54(1): 1372–1384. doi:10.1080/07853890.2022.2074535.
15. Li N, Yang WL, Cai MH, Chen X, Zhao R, Li MT, et al. Burden of gastroesophageal reflux disease in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *BMC Public Health*, 2023; 23: 582. doi:10.1186/s12889-023-15272-2.
16. Chen L, Yang X, Hu M, Zhou L, Ding Y, Wang Z, Liu Y, Shi R. Global, regional and national burdens of gastroesophageal reflux disease from 1990 to 2021 and projections to 2050: a finding from the Global Burden of Disease Study 2021. *BMC Public Health*, 2025; 25: 3943. doi:10.1186/s12889-025-25121-w.